TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21736587

Group type: EXPERIMENTAL
Intervention: Robenacoxib 5 mg/kg once daily for 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robenacoxib 10 mg/kg once daily for 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robenacoxib 2 mg/kg twice daily for 42 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robenacoxib 6 mg/kg twice daily for 42 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robenacoxib 10 mg/kg twice daily for 42 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21077526

Group type: EXPERIMENTAL
Intervention: Remifentanil (1 pg kg(‐1) IV bolus)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Fentanyl (0.5 microg kg(‐1) IV bolus)
Number of subjects: 72
Study: 18498919

Group type: EXPERIMENTAL
Intervention: Carvedilol (0.4 mg/kg/d in children <or=62.5 kg or 25 mg/d in children >62.5 kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 21
Study: 15880468

Group type: EXPERIMENTAL
Intervention: DM1 patients (MVICs)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal controls (MVICs)
Number of subjects: 25
Study: 12825804

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Dalteparin 2 x 5,000U)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard heparin (UFH) (5,000U bolus followed by infusion to raise APTT to 1.5 times control)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both LMWH and UFH
Number of subjects: 172
Study: 10213233

Group type: EXPERIMENTAL
Intervention: Needle tap
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Mechanized biopsy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Abort eyes (initial needle tap aborted to mechanized biopsy)
Number of subjects: 201
Study: 2714504

Group type: EXPERIMENTAL
Intervention: Squatting position during delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 929109

Group type: EXPERIMENTAL
Intervention: Benzilonium bromide (Ulcoban Prolongatum, Parke, Davis & Co.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Selective proximal vagotomy (SPV)
Number of subjects: 50
Study: 31849362

Group type: EXPERIMENTAL
Intervention: Interdisciplinary pain rehabilitation program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic evaluation from a societal perspective
Number of subjects: 0
Study: 30971276

Group type: EXPERIMENTAL
Intervention: Caffeinated gum (200 mg caffeine)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 17
Study: 28209122

Group type: EXPERIMENTAL
Intervention: Person-centred and health-promoting intervention
Number of subjects: 270

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 270
Study: 26385956

Group type: EXPERIMENTAL
Intervention: Combined intrahospital RIC + PostC in addition to primary PCI
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: PostC in addition to PCI
Number of subjects: 696

Group type: COMPARATOR
Intervention: Conventional PCI (control)
Number of subjects: 696
Study: 23349309

Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation in first remission (15 sibling donors and 16 unrelated donors)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Post-remission chemotherapy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Younger patients (<25 years)
Number of subjects: 85
Study: 21315644

Group type: EXPERIMENTAL
Intervention: Induction chemoradiation (60 Gy, 2 Gy/fraction; concomitant 5‐fluoro‐uracil infusion, 300 mg/m(2) per day, days 1‐5 for 6 weeks; cisplatin, 20 mg/m(2) per day, days 1‐5 during weeks 1 and 5) followed by maintenance gemcitabine (1000 mg/m(2) weekly, 3/4 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Induction gemcitabine (1000 mg/m(2) weekly for 7 weeks) followed by maintenance gemcitabine (1000 mg/m(2) weekly, 3/4 weeks)
Number of subjects: 119
Study: 19827653

Group type: EXPERIMENTAL
Intervention: Electrostimulation of the skeletal muscles (EMS) in addition to standard rehabilitation (n = 54)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard treatment (Control group, n = 47)
Number of subjects: 101
Study: 18261273

Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (20 ml once a day for 15 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluconazole (150 mg once a day for 15 days)
Number of subjects: 60
Study: 15238591

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg every 12 hours)
Number of subjects: 3987

Group type: COMPARATOR
Intervention: Unfractionated heparin (weight-adjusted intravenous)
Number of subjects: 3987

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3987

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3987
Study: 11600518

Group type: EXPERIMENTAL
Intervention: recombinant human GH (2.0 IU/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 22
Study: 9674293

Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Enalapril up to 20 mg/day
Number of subjects: 21
Study: 7979931

Group type: EXPERIMENTAL
Intervention: Isokinetic strength tests for plantar flexion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isokinetic strength tests for dorsiflexion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isokinetic strength tests for plantar flexion and dorsiflexion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experienced examiners (physical therapists)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isokinetic strength tests
Number of subjects: 0
Study: 3393620

Group type: EXPERIMENTAL
Intervention: Placebo and exposure therapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Imipramine and exposure therapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Imipramine and initial antiexposure instructions
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (nonanxious controls)
Number of subjects: 23
Study: 421317

Group type: EXPERIMENTAL
Intervention: 6-week intervention including total abstinence from caffeine and smoking, reduction of alcohol intake, and a physical conditioning program
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 81
Study: 30898938

Group type: EXPERIMENTAL
Intervention: SLN biopsy only
Number of subjects: 950

Group type: COMPARATOR
Intervention: SLN biopsy + pelvic lymphadenectomy
Number of subjects: 950
Study: 27614675

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid-based parenteral nutrition (Omegaven, Fresenius-Kabi, Germany) for 5 days postoperatively
Number of subjects: 312

Group type: COMPARATOR
Intervention: Structolipid alone (control group) for 5 days postoperatively
Number of subjects: 312
Study: 25878306

Group type: EXPERIMENTAL
Intervention: Highly cross‐linked polyethylene liners
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ultra‐high molecular weight polyethylene liners
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tantalum cups
Number of subjects: 46

Group type: COMPARATOR
Intervention: Titanium cups
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 46
Study: 23168119

Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Botulinum toxin injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical myotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Per oral endoscopic myotomy
Number of subjects: 0
Study: 22237467

Group type: EXPERIMENTAL
Intervention: O-3FA enteral immunoenhancing diet (IED)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Standard enteral nutrition (SEN)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (postoperative supplementation alone)
Number of subjects: 221
Study: 20655182

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine plus naltrexone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 17293025

Group type: EXPERIMENTAL
Intervention: Urodynamics at baseline
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Urodynamics at 6 months
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: BOOI > 65
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: BOOI >= 50
Number of subjects: 114
Study: 15300317

Group type: EXPERIMENTAL
Intervention: Standardized interviews (SCID-I, DSM-IV)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Routine diagnoses (discharge letters)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Clinically recognized cases
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Patients with higher depression scores
Number of subjects: 117
Study: 12161101

Group type: EXPERIMENTAL
Intervention: rhGM-CSF 5 mcg/kg/d for 4 days, IV
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rhG-CSF 10 mcg/kg/d for 4 days, IV
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline for 4 days, IV (placebo)
Number of subjects: 60
Study: 9527776

Group type: EXPERIMENTAL
Intervention: P‐HTIG plus Td vaccine
Number of subjects: 48

Group type: COMPARATOR
Intervention: P‐HTIG plus placebo
Number of subjects: 48
Study: 7637157

Group type: COMPARATOR
Intervention: Oral triazolam (0.25 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oral tizanidine (3 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oral clonidine (0.15 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Clonidine-tetracaine-phenylephrine group
Number of subjects: 63
Study: 2797970

Group type: EXPERIMENTAL
Intervention: Positive routines
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Graduated extinction
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 230893

Group type: COMPARATOR
Intervention: BCNU alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BCNU and VM-26
Number of subjects: 21
Study: 30977278

Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional Balloon
Number of subjects: 41
Study: 27633135

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) consumption, 200 ml daily for six weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 25875324

Group type: EXPERIMENTAL
Intervention: Immediate treatment group receiving business training, $150, and supervision and advising.
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Participants assigned to include household partners in the program.
Number of subjects: 1800
Study: 24422342

Group type: EXPERIMENTAL
Intervention: Monetary rewards group (chance to draw for a cash prize of $30.00 if CRT performances were at the 50th percentile or better)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (monetary rewards and control)
Number of subjects: 20
Study: 21052690

Group type: EXPERIMENTAL
Intervention: Caspase-1 5352 A allele carriers
Number of subjects: 104

Group type: COMPARATOR
Intervention: Other six polymorphisms related to inflammation
Number of subjects: 104
Study: 19436135

Group type: EXPERIMENTAL
Intervention: Light resistance exercise (15 min dumbbell exercise using 300 g brown‐rice‐filled fabric dumbbells)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (resting position)
Number of subjects: 7
Study: 16721686

Group type: EXPERIMENTAL
Intervention: Continual jejunal interposition (Group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Billroth II procedure (Group B)
Number of subjects: 34
Study: 15187817

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (up to 69 mg/dl)
Number of subjects: 14670

Group type: COMPARATOR
Intervention: Euglycaemic (80-109 mg/dl)
Number of subjects: 14670

Group type: EXPERIMENTAL
Intervention: Diabetic (>140 mg/dl)
Number of subjects: 14670

Group type: EXPERIMENTAL
Intervention: Low normal (70-79 mg/dl)
Number of subjects: 14670

Group type: EXPERIMENTAL
Intervention: Borderline diabetics (126-139 mg/dl)
Number of subjects: 14670

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (110-125 mg/dl)
Number of subjects: 14670
Study: 11209624

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Elective treatment cohort design with randomization
Number of subjects: 42
Study: 9440631

Group type: EXPERIMENTAL
Intervention: One-week course of triple therapy with bismuth subcitrate, metronidazole, and tetracycline plus ranitidine
Number of subjects: 250

Group type: COMPARATOR
Intervention: Six-week course of ranitidine 300 mg/day
Number of subjects: 250
Study: 8517902

Group type: EXPERIMENTAL
Intervention: Heparin (0.25 U/ml)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 15
Study: 3683021

Group type: EXPERIMENTAL
Intervention: Oxaprozin 600 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Indomethacin 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 1000 mg
Number of subjects: 8
Study: 29043548

Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Laparoscopic Gastric Plication (LGP)
Number of subjects: 70
Study: 27344212

Group type: EXPERIMENTAL
Intervention: Vitamin E‐coated dialyzers
Number of subjects: 32

Group type: COMPARATOR
Intervention: Heparin‐coated dialyzers
Number of subjects: 32
Study: 24636627

Group type: EXPERIMENTAL
Intervention: Diabetes-specific quality of life (QoL) measured by the Audit of Diabetes Dependent Quality of Life (ADDQoL19)
Number of subjects: 1876

Group type: EXPERIMENTAL
Intervention: Health status measured by SF-36
Number of subjects: 1876
Study: 22517782

Group type: EXPERIMENTAL
Intervention: Therapist-based bilateral arm training (TBAT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Robot-assisted bilateral arm training (RBAT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control treatment (CT)
Number of subjects: 42
Study: 20738840

Group type: EXPERIMENTAL
Intervention: SRK II
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pediatric IOL Calculator
Number of subjects: 24
Study: 18930629

Group type: EXPERIMENTAL
Intervention: Strain Doppler echocardiography
Number of subjects: 33

Group type: COMPARATOR
Intervention: Coronary flow velocity pattern
Number of subjects: 33
Study: 16214487

Group type: EXPERIMENTAL
Intervention: Four-dimensional model of the lower extremities after total hip arthroplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open MRI for validation of measurement error
Number of subjects: 0
Study: 12423180

Group type: EXPERIMENTAL
Intervention: 3 sets of weight training (S-3)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 1 set of weight training (S-1)
Number of subjects: 16
Study: 10423939

Group type: EXPERIMENTAL
Intervention: Itraconazole, 200 mg twice daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard palliative care (toenail trimming, cleaning, and soaking)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 52
Study: 7572630

Group type: COMPARATOR
Intervention: Intravenous heparin alone (Control group, n = 35)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined intravenous nitroglycerin and heparin (n = 31)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined intravenous isosorbide dinitrate and heparin (n = 30)
Number of subjects: 96
Study: 2285626

Group type: EXPERIMENTAL
Intervention: OPC-8212
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 6119025

Group type: EXPERIMENTAL
Intervention: Intervention group receiving outpatient clinic treatment for high GGT levels
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (random one-half of individuals with high GGT levels)
Number of subjects: 252
Study: 31442395

Group type: EXPERIMENTAL
Intervention: MB ultra-slim endoscope
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional ultra-slim endoscope
Number of subjects: 92
Study: 31562049

Group type: EXPERIMENTAL
Intervention: Mold-fermented cheese (MFC) 33.4 g daily for 3 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Non-MFC (processed cheese made from mozzarella cheese and cream cheese) 33.4 g daily for 3 months
Number of subjects: 71
Study: 28961832

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Nimotuzumab (gem + nimo)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Gemcitabine plus Placebo (gem + placebo)
Number of subjects: 192
Study: 26167086

Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/d) monotherapy
Number of subjects: 20
Study: 24506429

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Protease Inhibitor (PI) or Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Number of subjects: 37
Study: 21980934

Group type: EXPERIMENTAL
Intervention: Ultra-rush grass pollen immunotherapy with sublingual drops (Staloral)®
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 19095776

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 23371

Group type: EXPERIMENTAL
Intervention: Time to tumor progression (TTP)
Number of subjects: 23371

Group type: EXPERIMENTAL
Intervention: Response rate (RR)
Number of subjects: 23371

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 23371

Group type: EXPERIMENTAL
Intervention: Time to treatment failure
Number of subjects: 23371

Group type: COMPARATOR
Intervention: Comparison of trials using PFS, TTP, or time to treatment failure vs. RR
Number of subjects: 23371
Study: 16893378

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg d(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Atorvastatin (20 mg d(‐1))
Number of subjects: 8
Study: 14728265

Group type: EXPERIMENTAL
Intervention: Unscheduled, nighttime videoconferencing
Number of subjects: 0
Study: 10385063

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 mg twice per day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no calcitriol)
Number of subjects: 76
Study: 8727432

Group type: EXPERIMENTAL
Intervention: AutoInit ventilator settings
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control ventilator settings
Number of subjects: 30
Study: 1838978

Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg twice daily for 10 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Penicillin V (250 mg four times a day for 10 days)
Number of subjects: 95
Study: 6406440

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 183

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 183
Study: 31271705

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1046

Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 1046
Study: 30393209

Group type: EXPERIMENTAL
Intervention: CartiNovex plus tablet
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 26945383

Group type: EXPERIMENTAL
Intervention: Thyromental distance-based group
Number of subjects: 80
Study: 24929834

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 34
Study: 21933229

Group type: EXPERIMENTAL
Intervention: PM103 (0.1, 1.0, 10, 30, 100 or 300 mg)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: PM103
Number of subjects: 144
Study: 20668354

Group type: EXPERIMENTAL
Intervention: Irbesartan plus amiodarone (irbesartan 150 mg/d, n=43)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Amiodarone (n=42)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Irbesartan plus amiodarone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 85
Study: 17111172

Group type: EXPERIMENTAL
Intervention: Flupentixol (FLX) 5.7 +/- 1.4 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Haloperidol (HAL) 8.5 +/- 5.5 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Risperidone (RIS) 3.6 +/- 1.3 mg/day
Number of subjects: 35
Study: 15983331

Group type: EXPERIMENTAL
Intervention: Higher alanine aminotransferase and GGT values
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Raised GGT
Number of subjects: 1441
Study: 12144580

Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: esomeprazole 20 mg
Number of subjects: 24
Study: 9857976

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus Pindolol
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 8535670

Group type: EXPERIMENTAL
Intervention: Refluxing anastomosis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Anti-reflux anastomosis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Continent diversion
Number of subjects: 37
Study: 2212087

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.2% Triclosan and 0.5% zinc citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study: 75638

Group type: EXPERIMENTAL
Intervention: Kvadricult system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard laboratory gonococcal culture methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transport for 2 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transport for less than 24 hours or 'bedside' inoculation
Number of subjects: 0
Study: 31539622

Group type: EXPERIMENTAL
Intervention: semaglutide 1.0mg
Number of subjects: 577

Group type: COMPARATOR
Intervention: liraglutide 1.2mg
Number of subjects: 577
Study: 31307906

Group type: EXPERIMENTAL
Intervention: Home-based HPV self-sampling intervention
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Control group (HPV kit non-returners)
Number of subjects: 1083
Study: 28239995

Group type: EXPERIMENTAL
Intervention: ASSIST-linked brief intervention (BI)
Number of subjects: 806

Group type: COMPARATOR
Intervention: Informational pamphlet on risk associated with substance use
Number of subjects: 806
Study: 26106207

Group type: EXPERIMENTAL
Intervention: NIV + vibrating mesh nebulizer
Number of subjects: 10

Group type: COMPARATOR
Intervention: NIV + jet nebulizer
Number of subjects: 10